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Interleukin 10±Mediated Immunosuppression
by a Variant CD4 T Cell Epitope
of Plasmodium falciparum
protect against malaria (Nardin et al., 1989; Moreno et
al., 1991; Renia et al., 1993; Weiss et al., 1993; Takita-
Sonoda et al., 1996; Wang et al., 1996; Doolan and Hoff-
man, 1997; Stoute et al., 1997), and it remains unclear
whether and how the parasite can interfere with the
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ity of HLA-DR and HLA-DQ types (Calvo-Calle et al.,
1997). An HLA-A2-binding CD8 T cell epitope (327±335)
has been described that is also contained within thisSummary
polymorphic region (Tc2R) (Blum Tirouvanziam et al.,
1995; Plebanski et al., 1995). The finding of exclusively
The immunodominant CD4 T cell epitope region, Th2R,
nonsynonymous nucleotide changes in this epitope re-
of the circumsporozoite protein of Plasmodium falci-
gion suggested that its polymorphism is maintained by
parum is highly polymorphic. Such variation might be
the parasite to escape protective T cell responses (Good
utilized by the parasite to escape from or interfere et al., 1988). It has not been determined how CD4 or
with CD4 T cell effector functions. Here, we show that CD8 T cells exert such selective pressure on the malaria
costimulation with naturally occurring altered peptide parasite. We have recently shown that variation in an
ligands (APL) can induce a rapid change from IFNg adjacent region containing an HLA-B35-restricted CD8
production to the immunosuppresive mediator in- T cell epitope can lead to impairment of cytotoxic T
terleukin 10 (IL-10). This mechanism may contribute cell activity by altered peptide ligand (APL) antagonism
to the low levels of T cell responses observed to this (Gilbert et al., 1998). Antagonism has not been studied
pathogen in malaria-endemic areas. for the 326±347 region and, despite their likely impact
on the maintenance of variability, APL-based immune
Introduction evasion strategies by natural CD4 T cell epitope variants
have not been investigated for any infectious pathogen.
Despite repeated exposure to the parasite in malaria- Interferon gamma (IFNg) has been shown to mediate
endemic areas of the world, protective immunity to Plas- protection in animal models of malaria when secreted
modium falciparum takes many years to develop (Green- by Plasmodium-specific CD8 (Doolan et al., 1996; Pleb-
wood et al., 1987; Gupta et al., 1994). Consistent with anski et al., 1998) or CD4 T cells (Renia et al., 1993;
Weiss et al., 1993; Takita-Sonoda et al., 1996; Wang etthis observation, T cells specific for the preerythrocytic
al., 1996; Doolan and Hoffman, 1997). Both CD8 andmalaria antigens expected to participate in protective
CD4 T cells may also have lytic activity, but this effectorimmunity are found infrequently in naturally exposed
function may not correlate with protection (Plebanski etindividuals (Esposito et al., 1992; Doolan et al., 1993,
al., 1998). Protection in humans by immunization with1994; Aidoo et al., 1995; Plebanski et al., 1997). Malaria-
irradiated sporozoites (Nardin et al., 1989; Moreno etspecific T cell responses and, in some studies, even
al., 1991) and by the recently described RTS,S vaccineunrelated T cell responses are downregulated during
may also involve IFNg secretion by CS-specific CD4 Tthe course of malaria infection (Ho et al., 1986, 1988;
cells (Stoute et al., 1997). The present study addressesWangoo et al., 1990; Hviid et al., 1991). Th1 type re-
the impact of variation in the immunodominant CD4 Tsponses to preerythrocytic antigens by CD4 T cells can
cell epitope of CS on IFNg responses and on prolifera-
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tralia. natural variants tested of the aa 326±347 CS epitope,
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utilizing an assay that specifically assesses IFNg pro- Table 1. Binding of Natural Variant Peptides of the 326±347 aa
duction. Moreover, IFNg production was almost always Region of the Circumsporozoite Protein of Plasmodium
variant specific. falciparum
Lack of IFNg production to variant epitopes does not
Variant Sequence DR1302 DR1 DR15
necessarily imply lack of recognition by T cells. Prolifera-
V1 PSDQHIEKYLKTIQNSLSTEWS 11 11 11tion, as well as the secretion of Th2-type cytokines such
V2 PSDQHIEKYLKTIKNSLSTEWS 11 11 1as IL-4 and IL-10, can occur in the absence of IFNg
V3 PSDQHIEKYLQKIQNSLSTEWS 11 11 111
production (Mossman and Coffman, 1989; Evavold and V4 PSDQHIEKYLQKIKNSLSTEWS 11 11 1
Allen, 1991; Hollsberg et al., 1995; Jameson and Bevan, V5 PSDQHIEKYLQKIRNSLSTEWS 11 111 11
1995). We report here the identification of variants that, V6 PSDKHIKEYLNKIQNSLSTEWS 111 11 11
V7 PSDKHIEQYLNTIQNSLSTEWS 11 11 11in the absence of IFNg production, can selectively in-
V8 PSDKHIEQYLKKIQNSLSTEWS 2 2 111duce IL-10 and IL-4 or IL-10 alone. IFNg and proliferative
V9 PSDKHIEQYLKKIKNSISTEWS 11 111 11responses to one variant of the aa 326±347 epitope
pCLIP 11 11 NDof CS were inhibited by costimulation by other natural
pTT 11 ND 11
variants. Further characterization of this antagonistic
Polymorphic positions are marked in bold. Peptides were scoredeffect demonstrated a direct and rapid change in the
as high (111), medium (11), low (1), or undetectable (2) bindingIFNg to IL-10 production ratio. Recently, a new immuno-
capacity (IC50 , 1, 1±25, or 25±100 or .100 mg/ml, respectively)
regulatory CD4 T cell subset, Tr1, has been described to each HLA-DR allele tested. The universally binding epitopes from
that produces high levels of IL-10 and ocassionally TGFb TT (pTT) and CLIP (pCLIP) were used as positive controls. ND, not
(Groux et al., 1997). This T cell subset suppresses pri- determined.
mary proliferative T cell responses in vitro and downreg-
ulates autopathogenic T cell responses in vivo. The abil-
ity of altered peptide ligands to cause a rapid and direct be susceptible to heterologous boosting, limiting their
change toward such a suppressive phenotype may persistence in vivo.
therefore have important implications not only for infec- The aa 326±347 epitope region of CS has at least nine
tious diseases but also for the maintainance of the ho- natural variants (de la Cruz et al., 1987; Good et al.,
meostatic state. Indeed, autoreactive Th0 clones may 1988; Lockyer et al., 1989). Variant V6 of this region has
become TGFb producers upon APL stimulation (Wind- a broad spectrum of HLA-DR binding (Calvo-Calle et al.,
hagen et al., 1995). Here, IL-10 induction and IFNg down- 1997). Table 1 shows that variation occurs at positions
regulation by APL occured with T cell clones, T cell lines, 329, 333, 336, 337, and 339. Positions 329, 332, 333, and
and peripheral blood mononuclear cells, suggesting a 337 are dimorphic and positions 336 and 339 trimorphic
dominant suppressive effect in mixed T cell populations. (Table 1). Altering residues that contribute to HLA bind-
Such immunoregulatory interactions by natural poly- ing can be used as an immune evasion strategy for
morphic CD4 T cell epitopes may prevent elimination of protective T cell responses (Phillips et al., 1991; de
P. falciparum by IFNg-mediated protective mechanisms
Campos Lima et al., 1994). However, the aliphatic or
and contribute to the overall low level of responses to
aromatic residues that are potential HLA-DR-binding
malaria antigens in endemic areas. Such rapid IFNg/IL-
anchor positions (Hammer et al., 1994) are conserved (aa10 modulation could play a central role in susceptibility
327, 328, 331, and 335) (Table 1). The binding potential ofto a variety of autoimmune (O'Garra et al., 1997; Cobbold
all variants of this region to three common African al-and Waldmann, 1998; Mason and Powrie, 1998) and
leles (HLA-DRB1*1302, HLA-DRB1*0101, and HLA-DRB1*infectious diseases (Trinchieri, 1997; Hill, 1998).
1501) was studied by an in vitro binding assay (Daven-
port et al., 1995b). Table 1 shows that all variants boundResults
to HLA-DRB1*1501 and 8/9 to HLA-DRB1*1302 and
HLA-DRB1*0101 (IC50,100 mg/ml). The nonbindingIFNg Responses to aa 326±347 Are Found in Less
variant, V8, is absent in West Africa (de la Cruz et al.,than Half of Naturally Exposed Adult Gambians
1987; Good et al., 1988; Lockyer et al., 1989). No varia-and Show Limited Cross-Reactivity
tion decreased binding to all three alleles.With an average of five bites from malarious mosquitoes
Interferon g released from T cells may mediate protec-a year, a Gambian adult will have received in the order
tion from malaria in both animals and humans (Nardinof 100 infectious bites (Greenwood et al., 1987; Gupta
et al., 1989; Moreno et al., 1991; Renia et al., 1993; Weisset al., 1994). Despite this continual antigenic exposure,
et al., 1993; Doolan et al., 1996; Takita-Sonoda et al.,many Gambian donors fail to respond to the CS protein
1996; Wang et al., 1996; Doolan and Hoffman, 1997;in T cell proliferation assays (Good et al., 1988), even
Plebanski et al., 1998). Early IFNg production inducedto the ªuniversally bindingº variant of the aa 326±345
from the peripheral blood mononuclear cells (PBMC) ofepitope (Calvo-Calle et al., 1997). The reasons for this
malaria-exposed Gambian individuals by the nine aahave been unclear, but generalized immunosuppression
326±347 epitope variants displayed remarkable spe-is unlikely since responses to nonmalarial antigens are
cificity in ELISPOT assays (Figure 1A). Thus, all aafound at the expected frequencies. We initially tested the
changes could lead to lack of cross-recognition (3±8simple hypothesis that polymorphism in the aa 326±347
variants) in individuals reacting to different variants.immunodominant region of CS may generate variants
Cross-reactivity was investigated further by restimulat-with little cross-reactivity between them, even in poly-
ing in vitro and testing for cross-reactivity against allclonal responses. Thus, T cell responses might not be
variants after 14 days of expansion in culture (Figuredetected unless all variants were tested. Moreover, re-
sponses of donors living in endemic areas would not 1B). PBMC from malaria-exposed Gambian (D20, D41,
Altered Peptide Ligands Change IFNg/IL-10 Ratio
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Figure 1. Limited Cross-Reactivy of IFNg Re-
sponses to Naturally Occuring aa 326±347
Variants
(A) Peripheral blood mononuclear cells from
adult Gambians were stimulated with aa 326±
347 region variants in a 16 hr early IFNg re-
lease assay. All individuals were tested for
reactivity to PPD, with the expected re-
sponses seen (data not shown). Positivity
(filled squares) reflects a precursor frequency
of .10 cells/million of IFNg-producing cells
in response to the test epitope and 95% con-
fidence that the response is above back-
ground (p . 0.05). The 21 individuals where
IL-4 reactivity was tested in parallel are aster-
isked, and responses where both IFNg and
IL-4 were detected are shaded in gray. No
reactivity was detected to IL-4 alone. All
assays of IL-4 production were positive when
stimulated with PHA (data not shown). A fur-
ther 20 naive individuals tested for reactivity
to the same panel of variants failed to react
to any variant but reacted at the expected
frequencies to the control antigens PPD and
TT and to the mitogen PHA (data not shown).
(B) PBMC were cultured with the stated vari-
ant and tested 14 days later for cross-reactiv-
ity against the other variants by IFNg
ELISPOT. As well as Gambian donors 20, 41, 42, and 43, two naturally malaria-exposed European donors who reacted specifically to variants
V1 (donor 58) or V6 (donor 57) in ex vivo ELISPOT assays were also tested to evaluate the specificity of V1 or V6 stimulated short-term T cell
lines. Donors 41, 42, and 43 gave significant responses to V6 by ex vivo IFNg ELISPOT whereas donor 20 responses to V2 and V3 were
undetectable prior to in vitro expansion. Significant responses over background (SFU . 10/million and p . 0.05) for variants other than the
stimulating variant are indicated by hatched squares.
D42, D43) or malaria-exposed European (D57, D58) do- binding with a suboptimal dose of V6 had occurred in
a standard antagonism assay (Evavold and Allen, 1991).nors were cultured separately with variants and then
each line tested for reactivity against all the other vari- Figure 2 shows that responses to V6 could be partially
inhibited by coculture with some of the naturally oc-ants by IFNg ELISPOT. Only statistically significant re-
sponses from positive lines are shown. Figure 1B shows curring aa 326±347 variants. Surprisingly, the same vari-
ants could be inhibitory in different individuals (V2, V5,that all responses detectable after culture were either
monospecific or recognized only two of the nine variants. V7, and V9 in 2/4, 3/4, 4/4, and 2/4 individuals showed
.50% inhibition, p , 0.05). This putative antagonisticOut of 56 Gambian individuals tested, only 20 re-
sponded to any aa 326±347 region variant by IFNg pro- APL effect was investigated in detail for donor 57. The
response of donor 57 was specific to V6 (Figure 1B).duction, despite exposure of all individuals in the tested
age group (18±65) to P. falciparum (Greenwood et al., Over the 12 month period when IFNg antagonism assays
on freshly isolated PBMC were performed in donor 57,1987). Moreover, many infections in The Gambia are
coinfections of at least two different variant CS strains V5 and V7 were usually inhibitory (V5 in 11/12 and V7
11/13 experiments), despite variation in the absolute(Gilbert et al., 1998). We speculated that nonresponders
for IFNg production, which is a characteristic Th1 type level of inhibition (mean inhibition for V5 39% 6 7 SE,
p , 0.0005; V7 39% 6 9 SE, p , 0.0009). The universallylymphokine, might have generated instead a Th2 type
response, characterized by IL-4 production. However, binding HLA-DR peptide from TT (pTT) did not inhibit
V6 responses when used in antagonism assays (n 5 3),in the 21 Gambian adults assessed in parallel for stimula-
tion of early IFNg and IL-4 production, the few (3/21) and PPD responses were not inhibited by V5 or V6 (n 5
2) (data not shown). Figures 2B and 2C show a represen-individuals who responded by IL-4 secretion also se-
creted IFNg to the same stimulating variant (Figure 1A). tative assay in which proliferative responses in this do-
nor induced by V6 were strongly inhibited by V5 and V7None of the 20 malaria naive individuals tested reacted
to any of the variants in identical early lymphokine re- (n 5 6 assays). Significant inhibition by V5 but not V7
could be found even if it was presented on a differentlease assays.
antigen-presenting cell (APC) from V6 (Figure 2B). This
trans-inhibition by V5 was surprising and suggested aAltered Peptide Ligand Antagonism in aa 326±347
Naturally exposed individuals responded frequently to soluble suppressive mediator.
the ªuniversallyº binding variant V6 (Figure 1; Table 1)
(Calvo-Calle et al., 1997). PBMC from four naturally ex- Selective Induction of IL-10 Production
by aa 326±347 Region Variantsposed individuals who responded to variant V6 were
tested in an early IFNg secretion assay to assess the Both TGFb and IL-10 have been shown to have sup-
pressive effects on T cell proliferation (Moore et al.,effect of the presence of each one of the other variants
on the V6 response. These variants were added after 1993; Groux et al., 1997) and on cytokine production in
Immunity
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Figure 2. Altered Peptide Ligand Antago-
nism of V4 IFNg Responses and Proliferation
(A) Donors 41, 42, 43, and 57 respond to V6
by IFNg secretion. The impact of the presence
of the other variants on the V6 response was
assessed in an antagonism assay. Index pep-
tide was prepulsed first at 25 mg/ml onto
PBMC and the other variants an hour later at
50 mg/ml. The assay was then run as a stan-
dard ELISPOT. For donor 43, the antagonism
assay was repeated another two times with
similar results and for donor 57, another 12
times. Inhibition in donor 57 was observed
from 5 mg/ml of V5 or V7 (n 5 2 assays) (data
not shown). Proliferation to V6 was induced
from PBMC of donor 57 by mixing 1:1 irradi-
ated PBMC that had been sequentially pre-
pulsed with V6 followed by V5 (V6-V5) (B) or
V7 (V6-V7) (C) or prepulsed separately (V6/V5
or V6/V7), washed, and then mixed 1:1. Triti-
ated thymidine incorporation was monitored
from days 5±10. Results are shown as the
mean cpm 6 SE of triplicate samples. The
parallel IFNg ELISPOT assay with the same
PBMC showed SFU/million background of 1,
V6 response of 13, V6/V5 of 8 (36% inhibition),
and V6/V7 of 7 (45% inhibition). A representa-
tive experiment of six is shown. The average
inhibition for all experiments at the time of
peak proliferation for V6 by V5 was 62% 6
7 SE (sequential pulse) and 41% 6 19 SE
(separate pulse). For V7 it was 59% 6 13 SE
(sequential pulse) and 18% 6 9 SE (separate
pulse).
malaria (Ho et al., 1988). Figure 3 shows that inhibition a different TCR (data not shown), their reactivity pattern
to V5, V6, and V7 was also different. Thus, clone C4of early V6-induced IFNg responses by V5 could be
completely reversed by neutralizing anti-IL-10 but not failed to produce IL-10 to V5 and V7 but still showed
significant IL-10 induction by V6-V5 or V6-V7 costimula-anti-TGFb monoclonal antibodies (n 5 3 assays). As-
sessment of intracellular IL-10 content of a V6-specific tion. By contrast, clone C3 responded to V6, V7, and
V5 alone by IL-10 secretion. As expected, both clonesline (antagonizable by V5) from the same donor showed
doubling of IL-10 production in CD31 cells by V6/V5 responded by IFNg secretion to V6 but not V5 or V7
alone (data not shown). Fresh PBMC responses werecostimulation (Figures 3B and 3C). V5 and V7 also stimu-
lated early IL-10 release from the PBMC of donor 57 more similar to C3 reactivity, with IL-10 produced to V5
and V7 and partial downregulation by V5 of V6-inducedboth alone and when utilized with V6 in antagonism
assays, as detected by ELISPOT (Figure 3D). V5 and V7 IFNg responses (Figure 4F).
alone failed to stimulate significant IFNg or IL-4 produc-
tion at any concentration tested (5±100 mg/ml, n 5 6 Discussion
assays) (data not shown).
The effect of the V5 variant on lymphokine production CS-specific CD4 T cells capable of IFNg production can
protect against malaria in animals and are induced byby V6-specific T cells was further studied utilizing clones
from donor 57. Figure 4 shows that stimulation of V6- protective vaccination in humans (Nardin et al., 1989;
Tsuji et al., 1990; Renia et al., 1993; Rodrigues et al.,specific clones with V6 induced IFNg (C2, C5, C6) or
IFNg and IL-10 (C3, C4) secretion. Stimulation of these 1993; Weiss et al., 1993; Takita-Sonoda et al., 1996;
Wang et al., 1996; Doolan and Hoffman, 1997; Stouteclones with V6 in the presence of V5 led to downregula-
tion of IFNg production and a concomitant increase in et al., 1997). In the present study, we have observed
that selected APL variants of the immunodominant CD4IL-10. Thus, IL-10 production in CD4 T cell clones may
be increased by costimulation with an altered peptide T cell epitope of CS downregulate IFNg and proliferative
responses by preferential induction of IL-10.ligand. Oligoclonal responses (when clones were mixed)
reflected the dominant change in IFNg/IL-10 ratio to- Clones capable of high IL-10 secretion with low or
absent secretion of other lymphokines, such as IL-2,ward IL-10 by the presence of V5 on V6 responses (Fig-
ures 4C and 4D). No IL-4 could be detected under any IL-4, IL-5, or IFNg, have been denoted Tr1 (Groux et al.,
1997). Here, we show that the ratio of IFNg to IL-10 canexperimental condition in parallel ELISPOT assays.
Consistent with the observation that C3 and C4 use be changed during both rapid polyclonal responses and
Altered Peptide Ligands Change IFNg/IL-10 Ratio
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Figure 3. V5-Mediated Inhibition of V6 Re-
sponses Is Mediated by IL-10
(A) ELISPOTS were set up for antagonism
assays of V5 on V6 responses in donor 57 as
described in Figure 2 either alone or in the
presence of neutralizing mAbs to TGFb1 (10
ng/ml; Groux et al., 1997), interleukin 10 (10
ng/ml; Groux et al., 1997), or both. Increasing
the anti-TGFb mAb dose to 100 ng/ml failed
to reverse inhibition (n 5 2 assays, data not
shown). A representative experiment of three
is shown.
(B) The V6-specific V5 CD4 T cell line from
donor 58 was stimulated with HLA-DR15-
matched PBMC alone, pulsed with V6 (20 mg/
ml), or pulsed first with V6 and then with V5
(40 mg/ml). The phenotype of IL-10-positive
cells was analyzed by FACScan (CD3 for T
cells, CD14 for monocytes-macrophages,
and CD22 for activated B cells) and presented
as IL-10-positive cells per million. This proto-
col resulted in 100% inhibition of the V6 IFNg
response by V5 in the ELISPOT assay con-
ducted in parallel with the same samples
(data not shown).
(C) The total number of CD3-, CD14-, or
CD22-positive cells was unchanged under
conditions with and without antagonism dur-
ing this assay.
(D) Early IL-10 production (24 hr) by PBMC
from donor 57 in response to aa 326±347 re-
gion variants (empty bars) or in V6 antago-
nism assays (full bars) was tested by ELIS-
POT. A representative experiment of four is
presented utilizing variants at 50 mg/ml. Sig-
nificant IL-10 induction over control is marked
by an asterisk (p , 0.05). Titration of re-
sponses (range 5±100 mg/ml) showed maxi-
mal IL-10 induction by V5, V6, and V7 at 25±50
mg/ml and similarly for V6 (constant at 25 mg/
ml), V5, or V7 combinations in antagonism
assays (n 5 2). There was no significant IL-4
secretion to V6 at any concentration, alone
or in combination with V5 or V7 in six experi-
ments over a 6 month period. IL-10 and IL-4
assays used PHA and TT responses as posi-
tive controls.
when using long-term clones. Therefore, Tr1 may be an large family of APLs where single variants ªaltruisticallyº
minimize cross-reactivity may have been selected (Dav-inducible phenotype. Although we induced IL-10 pro-
duction by an altered peptide ligand, other stimuli may enport, 1995). However, the existence of groups of vari-
ants with antagonistic effects on the potentially protec-cause a similar rapid conversion. Indeed, changes in
lymphokine production could be a useful part of a natural tive IFNg response, in our case by an increase in IL-10
production, could provide a mechanism for the selectiveresponse, going from effector stages producing lympho-
kines that upregulate cellular to a later stage of downreg- maintenance of such a family.
Interleukin 10 is a pleiotropic lymphokine that canulation.
Specific aa variation at predicted non-MHC-binding directly or indirectly (via inhibition of accessory cell func-
tion) suppress IFNg, TNFa, GM-CSF, and LT productionresidues in the immunodominant CS-derived aa 326±
347 epitope suggested that it may be under an unusual by T cells and in the presence of monocyte/macro-
phages inhibits human T cell proliferation (Moore et al.,form of selective pressure. Altered peptide ligands of
HIV and HBV have been individually shown to provide 1993). By analyzing in detail responses to one CS variant,
V6, we have observed that IL-10 rather than IFNg secre-an escape strategy to these viruses (Bertoletti et al.,
1994; Klenerman et al., 1994). We have recently shown tion is promoted in response to specific APL combina-
tions. Natural variants of V6 were found that inhibitedhow parasites bearing two epitope variants of an HLA-
B35 CS epitope may gain a mutual advantage by recipro- the IFNg and proliferative V6-induced response of donor
57. These variants alone could induce IL-10 from freshlycal APL antagonism of CTL lytic activity (Gilbert et al.,
1998). The family of nine naturally occurring aa 326±347 isolated PBMC and from V6-specific T cell lines and
clones from the same donor. Moreover, IL-10 productionvariants displayed a remarkable lack of cross-reactivity
in IFNg assays. It was difficult to understand how a was further increased if they were used together with
Immunity
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Figure 4. Change in the IFNg to IL-10 Pro-
duction Ratio for V6-Specific Responses by
Costimulation with V5
(A±D) V6-specific T cell clones generated
from donor 57 were tested in antagonism
ELISPOT assays. IFNg, IL-4, and IL-10 pro-
duction were tested in parallel. Clones (C2,
C3, C4, C5, and C6) were utilized at 500 cells/
well with either HLA-matched PBMC or an
autologous Bcl line (at 50,000/well) as pre-
senters. Oligoclonal responses were as-
sessed by mixing all clones (M). IFNg re-
sponses shown in (A) and (C) and IL-10
responses in (B) and (D) are all from a single
experiment performed in duplicate and are
representative of four separate experiments
for clones C3 and C4, two for C5 and C6, and
one for C2. No significant IL-4 production was
detected, and presenters alone did not gen-
erate any lymphokine in response to any of
the peptides tested (data not shown). Signifi-
cant IFNg responses over background to V6
and inhibition of V6-induced responses by V5
were seen for all clones (p , 0.05). C3 and
C4 could give significant IL-10 responses to
V6 alone (p , 0.05). All clones showed signifi-
cant IL-10 responses to V6/V5 (p , 0.05), and
for C2, C4, C5, and C6 these were signifi-
cantly increased (p , 0.05) over V6 alone.
For clone C3, the increase in IL-10 for V6/V5
compared to V6 alone was consistently ob-
served (n 5 4 experiments) but did not reach
significance in any single experiment. (E)
Clones C3 and C4 were further tested for their
ability to respond by IL-10 production to V5
or V7 alone compared to V5 and V7 in the
presence of V6. The results shown are from
a single experiment performed in triplicate.
Clone C3 showed weak IL-10 reactivity over
background to V6 or V7 alone or V6/V7 (p ,
0.05) and strong reactivity to V5 alone or
V6/V5 (p , 0.001). Clone C4, by contrast,
failed here to respond significantly to V5, V6,
V7, or V6/V7 by IL-10 production but did so
to V6/V5 together (p , 0.05). Both clones responded to V6 but not V5 or V7 by IFNg production (data not shown). (F) Freshly isolated PBMC
from donor 57 were set up in parallel agonism and antagonism IL-10 and IFN ELISPOT assays. One of two representative assays is shown.
V6. Thus, IL-10 production and suppressive effects were These results suggest that naturally occuring aa 326±
347-specific CD4 T cell responses may change qualita-dominant over the IFNg response.
Two nonexclusive hypotheses may account for the tively by costimulation with APL-bearing parasites. The
in vivo consequences of a change in the ratio of IFNgstrong inhibitory effect in polyclonal responses of APL
downregulation of proliferation and IFNg production by to IL-10 production are extensive. IL-10 downreglates
MHC class II molecules on antigen-presenting cells, in-IL-10. The first hypothesis is that separate T cell popula-
tions react to V6 (by IFNg production) or V5 (by IL-10 hibits nitric oxide production, and prevents the priming
of Th1 T cells (Moore et al., 1993; Groux et al., 1997).production). When both are induced in the same culture,
the IL-10 induced by V5 may nonspecifically downregu- Thus, not only the specific IL-10-inducing parasite strain
but all malaria parasites in the host it infects may sec-late V6 IFNg responses. However, IFNg ELISPOT PPD
responses in the same donor were not inhibited by V5 ondarily benefit from this immune evasion strategy. This
is in contrast to antagonism at the effector phase ofcostimulation in parallel assays. Thus, IL-10 production
induced by V5 alone may not suffice to explain the ob- CD8 T cell responses where effects may be localized to
APL-infected cells (Davenport, 1995). In support of aserved inhibition of V6 responses. Alternatively, T cells
bearing the same TCR recognizing both V5 and V6 may trans-effect of IL-10 secretion, V5 inhibited V6 re-
sponses even when presented by separate APCs. Thebe susceptible to differential lymphokine regulation by
APL antagonism. In support of this hypothesis, T cell mechanism we observe for V5 is thus a suppressive-
dominant form of ªpartial agonismº rather than antago-clones did respond differentially by IFNg and IL-10 pro-
duction to V6 alone compared to V6 copresented with nism in its strict definition, although the latter term has
been used to cover several related phenomena (Jame-V5. However, it is likely that, once the IFNg/IL-10 ratio
decreases for a single clone, the IL-10 produced may son and Bevan, 1995). The same APL negatively affected
both rapid IFNg secretion and proliferation in parallelalso play a positive feedback role in promoting an IL-
10 response bias. assays in donor 57. This may make this immune evasion
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Experimental Proceduresmechanism singularly powerful, since these two effector
functions may be mediated by different memory T cell
Antigenssubsets (K. L. F. and M. P., unpublished data). V7 also
Peptides representing variant epitopes in aa 326±347 of the pre-
induced IL-10 from PBMC, but IL-10 neutralization did erythrocytic antigen circumsporozoite protein (CS) of P. falciparum
not reverse V6 inhibition, and additional suppressive were from Research Genetics (V1-V9) (Figure 1). Tetanus toxoid (TT)
(Evans Biomedical, UK), purified protein derivative from Mycobacte-mechanisms might be operating.
rium bovis (PPD) (Serumstatens Institut, Denmark), and the mitogenIFNg-secreting cells capable of changing toward in-
phytohaemoglutinin (PHA) (PHA-L, Wellcome Pharmaceuticals, UK)creased IL-10 secretion may not be restricted to the aa
were positive controls. Unless otherwise stated, antigens were uti-
326±347 epitope region in malaria and may indeed be lized at 25 mg/ml and PHA at 1 mg/ml.
a common occurrence. Thus, a recent study of malaria-
infected children and adults in Gabon observed that
HLA-DR Binding Assays
about half of the IL-10 producing CD4 and CD8 T cells Binding assays were carried out blind to all cellular results using
(induced nonspecifically) also coexpressed IFNg. The the principle of competitive binding with a promiscuously binding
invariant chain [Ii-(96-114)] biotinylated CLIP peptide (I*) as de-authors speculate that this might reflect an indirect feed-
scribed (Davenport et al., 1995a, 1995b). In brief, test peptides inback mechanism for inhibition of IFNg expression (Wink-
DMSO were serially diluted 1:10 in pH 5 buffer (0.02 M 2-N-morpholi-ler et al., 1999). We further suggest that such cells may
noethaqne-sulphonic acid in 0.1 M NaCl and 0.02% azide) and in-
represent transitory populations capable of the IFNg to cubated at 378C for 24 hr with I* (0.1 mg) and class II protein
IL-10 secretion change that we describe and thus may (0.15 mg). Solutions were neutralized with Tris-HCl (pH 7.5) before
provide a fertile ground for parasite immune evasion. transfer to 96-well BSA-blocked immunoplates (Nunc) precoated
with L-243 antibody. After 2 hr, plates were washed 33 with PBSPreliminary studies of rapid IL-10 secretion in adult
0.1% Tween (PBS-T) and 33 with PBS. Plates were developed withGambian donors suggested that the majority (10/12
avidin-horseradish peroxidase (ExtrAvidin; Sigma)/biotinylated anti-
tested) present high background levels of IL-10 secre- avidin (Sigma)/ExtrAvidin and developed with o-phenylene diamine
tion. How these high background levels may relate to (0.4 mg/ml) in phosphate citrate buffer. The reaction was monitored
malaria exposure remains to be determined (Plebanski, every 5 min at 495 nm and peak preequilibrium values used to
calculate the concentration of unlabeled peptide required to inhibitunpublished data). Utilizing a highly sensitive PCR tech-
50% binding of I* (IC50). The data was fitted to the binding algorithmnique, some CD4 T cells capable of early IFNg secretion
Y 5 (-(Ymax* X/(ic50 1 X) 1 background using GraphPad Prism 2.0.that also made IL-10 were detected in murine viral bron-
Binding assays were repeated in triplicate at least twice and the
chiolitis (Hussell et al., 1996). Moreover, T cell lines to mean calculated.
Borrelia burgdoferi capable of simultaneous IL-10 and
IFNg secretion are greatly increased in patients with
Cells and Culture Conditions
Lyme disease compared to controls. Further analysis of Blood donors were adult informed consent volunteers living in the
this T cell phenotype in a variety of disease states should villages of Brefet, Dampha Kunda, or Bakau, The Gambia, or volun-
teers with a known history of malaria exposure working at the Johnprovide insights into its possible role in homeostatic
Radcliffe Hospital, Oxford. Heparinized blood was separated onimmunoregulation and immune evasion. Rapid IFNg/IL-
Ficoll and the peripheral blood mononuclear cell (PMBC) fraction10 modulation is likely to play a pivotal role in autoim-
collected. Cells were resuspended in RPMI medium supplemented
mune (O'Garra et al., 1997; Cobbold and Waldmann, with 10% heat-inactivated human AB serum and 4 mM L-glutamine,
1998; Mason and Powrie, 1998) and infectious (Mahanty 100 U/ml penicillin, and 100 mg/ml streptomycin sulphate (RN10)
(all Gibco, UK) for immediate use in early ELISPOT assays or forand Nutman, 1995; Trinchieri, 1997; Hill, 1998) disease
restimulation and expansion in culture. For the latter, cells wereprogression.
cultured for 14 days with 25 mg/ml of the corresponding peptide atIL-10 induction by agonist/antagonist aa 326±347 CD4
1±2 3 106/ml in 1 ml well flat-bottom plates at 378C in a humid
epitopes is likely to prevent the priming of IFNg-produc- CO2 incubator, and interleukin 2 (10 U/ml, recombinant human IL-2,
ing cells (Moore et al., 1993; Groux et al., 1997) and may Lymphocult T-HP, Biotest, UK) was added on days 5 and 10. Cells
thus extend in time the benefit to the parasite population recovered on day 14 were washed in RPMI and used at 0.1 million
cells/well in ELISPOT as described below.by generating a population of susceptible hosts. Indeed,
unusually low levels of reactivity characterize T cell re-
sponses to P. falciparum (Doolan et al., 1993, 1994; Assay of Early Lymphokine Production
Unless otherwise stated, for early ELISPOT assays 0.4 millionPlebanski et al., 1997). Several alternative mechanisms
PBMC/well were cultured at 378C in a humid CO2 incubator withhave been suggested for the induction of malaria immu-
antigens for 16±24 hr in 96-well flat-bottom nitrocellulose platesnosuppression, such as inhibition of protein synthesis (MAIP 45S, Millipore, UK) precoated with anti-IFNg, anti-IL-4, or anti-
in hepatocytes and macrophages during the preerythro- IL-10 mAbs according to the manufacturer's instructions (Mabtech,
cytic stage (Frevert et al., 1998) and downregulation of Norway). In assays of antagonism, a suboptimal concentration index
peptide (25 mg/ml) was added to the assay 1 hr before the variantsmacrophage activity by blood stage parasites (Wangoo
(5±100 mg/ml). The next day, cells were removed and the plateset al., 1990; Schwarzer et al., 1992) but their relevance
washed 43 with phosphate-buffered saline (PBS) with 0.05% Tweento evasion of specific T cell protective responses is
20 (Sigma) followed by 23 in PBS, after which they were incubated
still unclear. But these do not explain why in malaria at room temperature for 1 hr with the corresponding biotinylated
extensive polymorphism is focused on CS T cell epi- second antibodies, followed by a washing as above and a 1 hr
incubation with a streptavidin-alkaline phosphatase conjugate. Aftertopes. The mechanism described here, which permits
washing, a precipitable alkaline phosphatase (AP) substrate wasrapid suppression of potentially protective responses,
added (Biorad). Data is expressed as the number of spot-formingmay explain through inefficient priming in an IL-10-rich
units (sfu) corresponding to areas of lymphokine secretion counted
milieu both general low levels of reactivity and the selec- with the aid of a dissection microscope per million PBMC. To assess
tion and maintainance of a family of allelic immunodomi- lymphokine production from specific T cell clones, HLA-matched
PBMC or lymphoblastoma Epstein-Barr transformed B cells (Bcl)nant epitopes.
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